These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15298036)

  • 1. Considerations in combination therapy: fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction.
    Manoharan G; Adgey AA
    Clin Cardiol; 2004 Jul; 27(7):381-6. PubMed ID: 15298036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
    Campbell KR; Ohman EM; Cantor W; Lincoff AM
    Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IIb/IIIa receptor blockade in acute myocardial infarction.
    Ferguson JJ; Taqi K
    Am Heart J; 1999 Aug; 138(2 Pt 2):S164-70. PubMed ID: 10426877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study].
    Franzosi MG
    Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828
    [No Abstract]   [Full Text] [Related]  

  • 7. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
    Maranian AM; Steinhubl SR
    Curr Cardiol Rep; 2002 Jul; 4(4):313-9. PubMed ID: 12052270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction.
    Cannon CP
    J Am Coll Cardiol; 1999 Nov; 34(5):1395-402. PubMed ID: 10551684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Vandoni P; Poli A; Fetiveau R; Cafiero F; D'Urbano M; De Servi S
    Ital Heart J Suppl; 2002 May; 3(5):539-43. PubMed ID: 12064193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
    JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies; single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction.
    Ronner E; van Domburg RT; van den Brand MJ; de Feyter PJ; Foley DP; van der Giessen WJ; Serruys PW; Simoons ML
    Eur Heart J; 2002 Oct; 23(19):1529-37. PubMed ID: 12242073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction.
    Santoro GM; Bolognese L
    Am Heart J; 2001 Feb; 141(2 Suppl):S26-35. PubMed ID: 11174356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis.
    Cannon CP
    Clin Cardiol; 1999 Aug; 22(8 Suppl):IV37-43. PubMed ID: 10492852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.